SEC Form 4 · accession 0000899243-17-014539
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christine Ocampo
Officer — See Remarks
Period of report
May 24, 2017
Accepted (ET)
May 26, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.50 | May 24, 2017 | A | 52,500 | A | — | May 23, 2027 | Common Stock | 52,500 | 52,500 | D |
Explanation of responses
- F1This option represents a right to purchase a total of 52,500 shares of the Issuer's Common Stock. 36,000 shares will vest ratably each month over three years beginning on May 24, 2017 (the "grant date"). 16,500 shares will vest on the later of achievement of a performance-related goal or the first anniversary of the grant date.
Remarks
Chief Financial and Compliance Officer